Aytu BioPharma (AYTU) vs Biofrontera (BFRI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Biofrontera (BFRI) has outperformed Aytu BioPharma (AYTU) over the past year, losing 9.0% versus a loss of 13.5%. Aytu BioPharma is the larger company by market cap ($22.3 million vs $13.6 million), about 1.6 times the size. On valuation, Biofrontera trades at a lower forward P/E (2.1x vs 13.2x for Aytu BioPharma).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | BFRI |
|---|---|---|
| Share price | $2.05 | $0.9188 |
| Market cap | $22.28M | $13.65M |
| 1-day change | 0.00% | -1.77% |
| YTD return | -21.15% | +61.19% |
| 1-year return | -13.50% | -9.03% |
| 5-year return | -96.13% | — |
| Forward P/E | 13.23 | 2.14 |
| EPS (TTM) | $-1.16 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $1.66 |
| 52-week low | $1.80 | $0.555 |
| Distance from 52-week high | -33.22% | -44.65% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +371.71% | +553.03% |
| Average volume | 34.22K | 547.45K |
| Shares outstanding | 10.87M | 14.85M |
| Employees | 75 | 84 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Healthcare · Drug Manufacturers - Specialty & Generic · 75 employees
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Healthcare · Drug Manufacturers - Specialty & Generic · 84 employees
AYTU vs BFRI FAQ
Which is bigger, Aytu BioPharma or Biofrontera?
Aytu BioPharma (AYTU) is larger, with a market capitalization of $22.28M compared with $13.65M for Biofrontera (BFRI).
Which stock has performed better over the past year, AYTU or BFRI?
BFRI returned -9.03% over the past 12 months, compared with -13.50% for AYTU (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Biofrontera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.